News
Mark Dawson named head of Roche's pRED unit
Roche has appointed leading Australian cancer researcher Mark Dawson to lead its pRED R&D division, as the company prepares for a steep patent cliff.
News
Helus' psychedelic drug DMT 'could help treat depression'
Helus' psychedelic derived from ayahuasca, a brew used in shamanistic rituals in South America, has shown promise as a treatment for depression.
News
Roche trial offers hope to patients with rare kidney disease
A study of Roche's Gazyva has raised the prospect of a first approved therapy for the rare kidney disorder primary membranous nephropathy.
News
AI in drug development news round-up
Recent developments in biopharma AI include an alliance between Thermo and Datavant, plus news from Insilico, Evinova, BPGbio, Evogene, and AMPLY.
R&D
The role of the opioid pathway in schizophrenia and bipolar ...
Psychiatry has spent decades focused on dopamine, serotonin, norepinephrine, and glutamate.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
